<p>Bright Minds Biosciences（納斯達克代碼：DRUG - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “持有” 評級下調至 “賣出” 評級。</p>
<ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
<p>其他幾位股票研究分析師也對 DRUG 發佈了報告。Cantor Fitzgerald 在 12 月 1 日的研究報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。BTIG Research 將 Bright Minds Biosciences 的目標價格從 72.00 美元提高至 147.00 美元，並在週二的報告中給予該公司 “買入” 評級。Chardan Capital 在 1 月 2 日的研究報告中重申了 “買入” 評級，並設定了 80.00 美元的目標價格。HC Wainwright 在 12 月 30 日的研究報告中重申了 “買入” 評級，並設定了 115.00 美元的目標價格。最後，Robert W. Baird 在週三設定了 Bright Minds Biosciences 的目標價格為 142.00 美元。七位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，Bright Minds Biosciences 目前的共識評級為 “適度買入”，平均目標價格為 115.40 美元。</p>
<p><strong>查看我們對 Bright Minds Biosciences 的最新分析</strong></p>
<h2>Bright Minds Biosciences 股價下跌 3.6%</h2>
<ul>
<li>Bright Minds Biosciences 股票飆升近 1500%</li>
</ul>
<p>DRUG 在週五開盤價為 86.75 美元。該公司的市值為 6.7578 億美元，市盈率為-71.11，貝塔值為-6.15。Bright Minds Biosciences 的 12 個月低點為 23.17 美元，12 個月高點為 123.75 美元。該股票的 50 日移動平均線為 73.17 美元，200 日移動平均線為 53.59 美元。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金最近對該股票的持倉進行了調整。高盛集團在第一季度購買了 Bright Minds Biosciences 的新股份，價值約為 802,000 美元。Sio Capital Management LLC 在第二季度將其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 目前擁有 512,338 股該公司的股票，價值為 13,377,000 美元，在上個季度又增持了 4,776 股。新澤西州警察和消防員退休系統在第二季度購買了 Bright Minds Biosciences 的新股份，價值約為 28,000 美元。AdvisorShares Investments LLC 在第二季度將其在 Bright Minds Biosciences 的持倉增加了 28.4%。AdvisorShares Investments LLC 目前擁有 14,481 股該公司的股票，價值為 378,000 美元，在此期間又增持了 3,200 股。最後，摩根大通在第三季度將其在 Bright Minds Biosciences 的持股增加了 142.3%。摩根大通目前擁有 5,265 股該公司的股票，價值為 319,000 美元，在上個季度又增持了 3,092 股。當前 40.52% 的股票由機構投資者持有。</p>
<h2>Bright Minds Biosciences 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Bright Minds Biosciences Inc 在納斯達克以 DRUG 為交易代碼，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創造源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等未滿足的需求。</p>
<p>該公司的主要候選藥物 BMB-101 是一種口服 5-HT2A 受體調節化合物，正在臨牀開發中，針對情緒和焦慮障礙。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Bright Minds Biosciences 更好</li>
<li>華爾街選股者評選 2026 年第一隻股票</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>請勿刪除，立即閲讀</li>
<li>家族信託如何幫助保護您的財富</li>
<li>市場恐慌：特朗普剛剛對您的股票投下了一顆炸彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Bright Minds Biosciences 嗎？</h2>
<p>在您考慮 Bright Minds Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Bright Minds Biosciences 並不在名單上。</p>
<p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DRUG

<p>華爾街禪將 Bright Minds Biosciences（納斯達克代碼：DRUG）的評級從 “持有” 下調至 “賣出”。儘管如此，幾位分析師仍然保持樂觀的展望，Cantor Fitzgerald 重申了 “增持” 評級，而 BTIG Research 則將目標價格上調至 147 美元。該股票的共識評級為 “適度買入”，平均目標價格為 115.40 美元。Bright Minds 專注於開發針對心理健康和神經退行性疾病的治療藥物，其主要候選藥物正在針對情緒和焦慮障礙進行臨牀開發</p>

<p>Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>Bright Minds Biosciences（納斯達克代碼：DRUG - 獲取免費報告）在週六發佈的研究報告中被華爾街 Zen 的投資分析師從 “持有” 評級下調至 “賣出” 評級。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
</div><p>Several other equities research analysts have also issued reports on DRUG. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. BTIG Research increased their price target on Bright Minds Biosciences from $72.00 to $147.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $80.00 price objective on shares of Bright Minds Biosciences in a research note on Friday, January 2nd. HC Wainwright reiterated a &#34;buy&#34; rating and set a $115.00 price objective on shares of Bright Minds Biosciences in a research report on Tuesday, December 30th. Finally, Robert W. Baird set a $142.00 target price on shares of Bright Minds Biosciences in a report on Wednesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Bright Minds Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $115.40.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對 DRUG 發佈了報告。Cantor Fitzgerald 在 12 月 1 日的研究報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。BTIG Research 將 Bright Minds Biosciences 的目標價格從 72.00 美元提高至 147.00 美元，並在週二的報告中給予該公司 “買入” 評級。Chardan Capital 在 1 月 2 日的研究報告中重申了 “買入” 評級，並設定了 80.00 美元的目標價格。HC Wainwright 在 12 月 30 日的研究報告中重申了 “買入” 評級，並設定了 115.00 美元的目標價格。最後，Robert W. Baird 在週三設定了 Bright Minds Biosciences 的目標價格為 142.00 美元。七位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “持有” 評級。根據 MarketBeat.com 的數據，Bright Minds Biosciences 目前的共識評級為 “適度買入”，平均目標價格為 115.40 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Bright Minds Biosciences</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Bright Minds Biosciences 的最新分析</strong></p>
</div><h2>Bright Minds Biosciences Trading Down 3.6%</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 股價下跌 3.6%</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票飆升近 1500%</li>
</ul>
</div><p>DRUG opened at $86.75 on Friday. The firm has a market cap of $675.78 million, a P/E ratio of -71.11 and a beta of -6.15. Bright Minds Biosciences has a 12 month low of $23.17 and a 12 month high of $123.75. The stock has a 50-day moving average of $73.17 and a 200 day moving average of $53.59.</p>
<div class="lb-trans"><p>DRUG 在週五開盤價為 86.75 美元。該公司的市值為 6.7578 億美元，市盈率為-71.11，貝塔值為-6.15。Bright Minds Biosciences 的 12 個月低點為 23.17 美元，12 個月高點為 123.75 美元。該股票的 50 日移動平均線為 73.17 美元，200 日移動平均線為 53.59 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. bought a new stake in Bright Minds Biosciences during the 1st quarter valued at about $802,000. Sio Capital Management LLC grew its stake in Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company's stock worth $13,377,000 after acquiring an additional 4,776 shares in the last quarter. Police &amp; Firemen s Retirement System of New Jersey purchased a new position in shares of Bright Minds Biosciences during the second quarter worth approximately $28,000. AdvisorShares Investments LLC increased its position in shares of Bright Minds Biosciences by 28.4% during the second quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company's stock worth $378,000 after acquiring an additional 3,200 shares during the period. Finally, JPMorgan Chase &amp; Co. raised its stake in shares of Bright Minds Biosciences by 142.3% during the third quarter. JPMorgan Chase &amp; Co. now owns 5,265 shares of the company's stock valued at $319,000 after acquiring an additional 3,092 shares in the last quarter. 40.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金最近對該股票的持倉進行了調整。高盛集團在第一季度購買了 Bright Minds Biosciences 的新股份，價值約為 802,000 美元。Sio Capital Management LLC 在第二季度將其在 Bright Minds Biosciences 的持股增加了 0.9%。Sio Capital Management LLC 目前擁有 512,338 股該公司的股票，價值為 13,377,000 美元，在上個季度又增持了 4,776 股。新澤西州警察和消防員退休系統在第二季度購買了 Bright Minds Biosciences 的新股份，價值約為 28,000 美元。AdvisorShares Investments LLC 在第二季度將其在 Bright Minds Biosciences 的持倉增加了 28.4%。AdvisorShares Investments LLC 目前擁有 14,481 股該公司的股票，價值為 378,000 美元，在此期間又增持了 3,200 股。最後，摩根大通在第三季度將其在 Bright Minds Biosciences 的持股增加了 142.3%。摩根大通目前擁有 5,265 股該公司的股票，價值為 319,000 美元，在上個季度又增持了 3,092 股。當前 40.52% 的股票由機構投資者持有。</p>
</div><h2>Bright Minds Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc 在納斯達克以 DRUG 為交易代碼，是一家臨牀階段的生物技術公司，專注於開發用於心理健康和神經退行性疾病的新型小分子治療藥物。該公司的研究利用專有化學平台創造源自迷幻藥結構的調節血清素和神經保護化合物。Bright Minds 旨在通過口服治療解決重度抑鬱症、創傷後應激障礙和阿爾茨海默病等未滿足的需求。</p>
</div><p>The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 BMB-101 是一種口服 5-HT2A 受體調節化合物，正在臨牀開發中，針對情緒和焦慮障礙。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Bright Minds Biosciences 更好</li>
<li>華爾街選股者評選 2026 年第一隻股票</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>請勿刪除，立即閲讀</li>
<li>家族信託如何幫助保護您的財富</li>
<li>市場恐慌：特朗普剛剛對您的股票投下了一顆炸彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Bright Minds Biosciences 嗎？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Bright Minds Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Bright Minds Biosciences 並不在名單上。</p>
</div><p>While Bright Minds Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bright Minds Biosciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bright Minds Biosciences（納斯達克股票代碼：DRUG）在 Wall Street Zen 被下調至 “賣出” 評級